{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:57:41Z","timestamp":1794895061657,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13555-026-01711-3","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T19:38:10Z","timestamp":1773689890000},"page":"2169-2180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes\u2014IL PSO (Italian Landscape Psoriasis)"],"prefix":"10.1007","volume":"16","author":[{"given":"Luciano","family":"Ibba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3780-5318","authenticated-orcid":false,"given":"Sara","family":"Di Giulio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Sacchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santo Raffaele","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Giacalone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Pedron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Caproni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Cammarata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Cuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Altomare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M. G.","family":"Brunasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zerbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Caccavale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo G.","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Lora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"1711_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"JE Greb","year":"2016","unstructured":"Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082. https:\/\/doi.org\/10.1038\/nrdp.2016.82.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1711_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010058","volume":"19","author":"L Puig","year":"2017","unstructured":"Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci. 2017;19(1):58. https:\/\/doi.org\/10.3390\/ijms19010058.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1711_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2425029","volume":"35","author":"L Ibba","year":"2024","unstructured":"Ibba L, Di Giulio S, Gargiulo L, et al. Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study. J Dermatolog Treat. 2024;35(1):2425029. https:\/\/doi.org\/10.1080\/09546634.2024.2425029.","journal-title":"J Dermatolog Treat"},{"key":"1711_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01566-0","author":"M Ponikowska","year":"2025","unstructured":"Ponikowska M, Hill L, Lee CS, et al. Cardiovascular disease and psoriasis. Dermatol Ther. 2025. https:\/\/doi.org\/10.1007\/s13555-025-01566-0.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1711_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.det.2024.02.007","volume":"42","author":"M Taliercio","year":"2024","unstructured":"Taliercio M, Lebwohl M. Psoriasis comorbidities and their treatment impact. Dermatol Clin. 2024;42(3):405\u201316. https:\/\/doi.org\/10.1016\/j.det.2024.02.007.","journal-title":"Dermatol Clin"},{"issue":"6","key":"1711_CR6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/1346-8138.15840","volume":"48","author":"F Yamazaki","year":"2021","unstructured":"Yamazaki F. Psoriasis: comorbidities. J Dermatol. 2021;48(6):732\u201340. https:\/\/doi.org\/10.1111\/1346-8138.15840.","journal-title":"J Dermatol"},{"issue":"Suppl. 1 to No.","key":"1711_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23736\/S2784-8671.21.07132-2","volume":"157","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venereol. 2022;157(Suppl. 1 to No. 1):1\u201378. https:\/\/doi.org\/10.23736\/S2784-8671.21.07132-2.","journal-title":"Ital J Dermatol Venereol"},{"issue":"11","key":"1711_CR8","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398. https:\/\/doi.org\/10.1111\/jdv.16915.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1711_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105485","volume":"111","author":"K Kridin","year":"2025","unstructured":"Kridin K, Bieber K, Vorobyev A, et al. Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis. EBioMedicine. 2025;111:105485. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105485.","journal-title":"EBioMedicine"},{"issue":"4","key":"1711_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s13555-020-00409-4","volume":"10","author":"DMW Balak","year":"2020","unstructured":"Balak DMW, Gerdes S, Parodi A, Salgado-Boquete L. Long-term safety of oral systemic therapies for psoriasis: a comprehensive review of the literature. Dermatol Ther. 2020;10(4):589\u2013613. https:\/\/doi.org\/10.1007\/s13555-020-00409-4.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1711_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/24755303231201336","volume":"8","author":"P Kingston","year":"2023","unstructured":"Kingston P, Blauvelt A, Strober B, Armstrong AW. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. J Psoriasis Psoriatic Arthritis. 2023;8(4):156\u201365. https:\/\/doi.org\/10.1177\/24755303231201336.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"1","key":"1711_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase\u00a03 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2022.08.061.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1711_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase\u00a03 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29\u201339. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.002.","journal-title":"J Am Acad Dermatol"},{"key":"1711_CR14","unstructured":"Sotyktu. European Medicines Agency (EMA). Jan 24, 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sotyktu. Accessed Dec 7, 2025."},{"issue":"1","key":"1711_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2307489","volume":"35","author":"T Hagino","year":"2024","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan. J Dermatolog Treat. 2024;35(1):2307489. https:\/\/doi.org\/10.1080\/09546634.2024.2307489.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1711_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/ced\/llae312","volume":"50","author":"T Hagino","year":"2024","unstructured":"Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: a 24-week real-world study. Clin Exp Dermatol. 2024;50(1):130\u20133. https:\/\/doi.org\/10.1093\/ced\/llae312.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1711_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2199108","volume":"34","author":"L Ibba","year":"2023","unstructured":"Ibba L, Gargiulo L, Alfano A, et al. Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study. J Dermatolog Treat. 2023;34(1):2199108. https:\/\/doi.org\/10.1080\/09546634.2023.2199108.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1711_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/1346-8138.17074","volume":"51","author":"S Imafuku","year":"2024","unstructured":"Imafuku S, Okubo Y, Tada Y, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, phase\u00a03 trial. J Dermatol. 2024;51(3):365\u201379. https:\/\/doi.org\/10.1111\/1346-8138.17074.","journal-title":"J Dermatol"},{"issue":"4","key":"1711_CR19","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s13555-024-01147-7","volume":"14","author":"A Egeberg","year":"2024","unstructured":"Egeberg A, Hawkes JE, Somani N, et al. Sustained improvements in clinical and patient-reported outcomes and quality of life through 5\u00a0years among ixekizumab-treated patients with complete clearance of scalp psoriasis by week\u00a060. Dermatol Ther. 2024;14(4):1007\u201318. https:\/\/doi.org\/10.1007\/s13555-024-01147-7.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1711_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/1346-8138.17115","volume":"51","author":"M Valenti","year":"2024","unstructured":"Valenti M, Gargiulo L, Ibba L, et al. Effectiveness of ixekizumab for the treatment of moderate-to-severe plaque psoriasis with involvement of difficult-to-treat areas: a 52-week multicenter retrospective study. J Dermatol. 2024;51(6):839\u201343. https:\/\/doi.org\/10.1111\/1346-8138.17115.","journal-title":"J Dermatol"},{"issue":"2","key":"1711_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020495","volume":"13","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, et al. Effectiveness, tolerability, and drug survival of risankizumab in a real-world setting: a three-year retrospective multicenter study-IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Clin Med. 2024;13(2):495. https:\/\/doi.org\/10.3390\/jcm13020495.","journal-title":"J Clin Med"},{"key":"1711_CR22","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.18672","volume":"104","author":"E Sonkoly","year":"2024","unstructured":"Sonkoly E, Maul JT, Megna M, et al. Guselkumab in patients with scalp psoriasis: a post hoc analysis of the VOYAGE 2 phase\u00a0III randomized clinical trial. Acta Derm Venereol. 2024;104:adv18672. https:\/\/doi.org\/10.2340\/actadv.v104.18672.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1711_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/09546634.2016.1249820","volume":"28","author":"K Reich","year":"2017","unstructured":"Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase\u00a03 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017;28(4):282\u20137. https:\/\/doi.org\/10.1080\/09546634.2016.1249820.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"1711_CR24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3724\/zdxbyxb-2025-0432","volume":"54","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen T, Pan W, Li Z. A real world study on the effectiveness and safety of deu-cravacitinib in the treatment of moderate-to-severe plaque psoriasis in China. J Zhejiang Univ (Med Sci). 2025;54(5):653\u201360. https:\/\/doi.org\/10.3724\/zdxbyxb-2025-0432.","journal-title":"J Zhejiang Univ (Med Sci)"},{"issue":"1","key":"1711_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","volume":"161","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Lebwohl M, Warren RB, et al. Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3\u00a0years: an open-label extension of randomized clinical trials. JAMA Dermatol. 2025;161(1):56\u201366. https:\/\/doi.org\/10.1001\/jamadermatol.2024.4688.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1711_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.36849\/JDD.8616","volume":"24","author":"M Shah","year":"2025","unstructured":"Shah M, Burshtein J, Zakria D, et al. A review of the safety and efficacy of deucravacitinib for plaque psoriasis: an expert consensus panel. J Drugs Dermatol. 2025;24(2):147\u201355. https:\/\/doi.org\/10.36849\/JDD.8616.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1711_CR27","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s11096-025-01896-1","volume":"47","author":"K Zhao","year":"2025","unstructured":"Zhao K, Xiao S, Zhao Y, Tu C. Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System. Int J Clin Pharm. 2025;47(5):1215\u201323. https:\/\/doi.org\/10.1007\/s11096-025-01896-1.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"1711_CR28","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s11096-025-01980-6","volume":"47","author":"H Tan","year":"2025","unstructured":"Tan H, Chen X, Ou X, Chen Y. Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database. Int J Clin Pharm. 2025;47(6):1821\u20139. https:\/\/doi.org\/10.1007\/s11096-025-01980-6.","journal-title":"Int J Clin Pharm"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01711-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01711-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01711-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:38:32Z","timestamp":1775101112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01711-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1711"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01711-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mario Valenti has been a consultant and\/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, AbbVie, Boehringer Ingelheim, Almirall, UCB and Difa Cooper. Luciano Ibba has been a consultant and\/or speaker and has served as an advisory board member for Almirall and LEO Pharma. Piergiorgio Malagoli has been a speaker for AbbVie, Eli Lilly, Novartis, Janssen-Cilag, Celgene, Leo Pharma, and Almirall. Anna Balato has received honoraria for participation in advisory boards, meetings, or as a speaker for AbbVie, Celgene, Janssen-Cilag, Eli Lilly, Novartis Pharma, Pfizer, Sanofi-Genzyme, and UCB Pharma. Angelo V. Marzano reports consultancy\/advisory boards disease-relevant honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, Leopharma, Novartis, Pfizer, Sanofi, and UCB. Matteo Megna acted as a speaker or consultant for AbbVie, Eli Lilly, Janssen, Leo Pharma, and Novartis. Diego Orsini has been a speaker and\/or consultant for AbbVie, Leo Pharma, UCB, Bristol-Myers Squibb, and Boehringer Ingelheim. Emanuele Trovato is involved in an intermittent project focused on consulting and\/or advisory relationships and\/or travel-congress support with Eli Lilly, Novartis, Janssen-Cilag, AbbVie, and Almirall. Serena Giacalone has received honoraria from AbbVie, Johnson and Johnson, Almirall, Sanofi, Leo Pharma, and Novartis. Simone Ribero has served as an advisory board member and\/or consultant and has received fees and speaker\u2019s honoraria or has participated in clinical studies for AbbVie, Almirall, Leo Pharma, Eli Lilly, Novartis, Pfizer, and Sanofi Genzyme. Andrea Carugno has been a consultant and\/or speaker for AbbVie, Leo Pharma, Eli Lilly, Novartis, Janssen-Cilag, Amgen, Almirall, UCB Pharma, and Boehringer Ingelheim. Giovanni Paolino received speaker\u2019s honoraria from AbbVie, Janssen, UCB and Pierre Fabre Pharma. Antonio Costanzo has served as an advisory board member, consultant, and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Leo Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB Pharma. Alessandra Narcisi has served on advisory boards, received honoraria for lectures, and research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen, and Boehringer Ingelheim. Carlo G. Carrera has served as a board participant or speaker for AbbVie, Eli Lilly, Janssen, Novartis, Celgene, Almirall, and Leo Pharma. Sara Di Giulio, Lidia Sacchelli, Santo R. Mercuri, Alexia Pedron, Marzia Caproni, Edoardo Cammarata, Aldo Cuccia, Andrea Altomare, Alexandra M. G. Brunasso, Valentina Dini, Nicola Zerbinati, Francesco Messina, Stefano Caccavale, Luca Potestio, Federico Bardazzi and Viviana Lora have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional review board approval was exempted as the study protocol did not deviate from standard clinical practice. All patients received deucravacitinib as in good clinical practice, in accordance with Italian guidelines. All included patients had provided written consent for a retrospective study of data collected during routine clinical practice (demographics, clinical scores). The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Data collection and handling complied with applicable laws, regulations, and guidance regarding patient protection, including patient privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}